Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $85,000.

  • Voyager Therapeutics' Cash from Financing Activities rose 507.14% to $85,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 98.90%. This contributed to the annual value of $114.0 million for FY2024, which is 238.88% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Cash from Financing Activities stood at $85,000, which was down 83.43% from $513,000 recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Cash from Financing Activities registered a high of $112.9 million during Q1 2024, and its lowest value of $12,000 during Q1 2022.
  • Over the past 3 years, Voyager Therapeutics' median Cash from Financing Activities value was $513,000 (recorded in 2025), while the average stood at $13.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 260,783.33% in 2023, then tumbled by 99.93% in 2025.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Cash from Financing Activities stood at $227,000 in 2021, then climbed by 21.59% to $276,000 in 2022, then skyrocketed by 66.67% to $460,000 in 2023, then rose by 24.78% to $574,000 in 2024, then skyrocketed by 507.14% to $85,000 in 2025.
  • Its Cash from Financing Activities was $85,000 in Q3 2025, compared to $513,000 in Q2 2025 and $82,000 in Q1 2025.